-
3 days ago | 
pharmaphorum.com | Nicole Raleigh
At ASCO 2025, Servier presented data in the IDH-mutated cancer space. Onsite at McCormick Place in Chicago, pharmaphorum web editor Nicole Raleigh spoke with Becky Martin, chief US medical at Servier about the key data from the company’s Tibsovo and Voranigo programmes, as well as the implications for patients and the wider themes of the Congress this year. Listen to this and other interviews from ASCO 2025 here.
-
4 days ago | 
pharmaphorum.com | Nicole Raleigh
At ASCO 2025, pharmaphorum web editor Nicole Raleigh sat down to discuss key highlights from the Congress with EVERSANA experts.
-
4 days ago | 
pharmaphorum.com | Nicole Raleigh
Only approximately two out of 10 people in the US and three out of 10 people in Europe with certain rare, advanced blood cancers receive access to CAR T-cell therapy. So it is that the CAR-T Vision Coalition aims to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy.
-
4 days ago | 
pharmaphorum.com | Nicole Raleigh
Boehringer Ingelheim’s data presented at ASCO 2025 reflected the company’s broad pipeline and growing body of evidence supporting innovative therapies for various cancers. In a pharmaphorum podcast recorded onsite at the Congress, web editor Nicole Raleigh spoke with Itziar Canamasas, global head of oncology at Boehringer Ingelheim, for a discussion of the unmet needs in oncology and some of the specifics of the company’s data presentations.
-
5 days ago | 
pharmaphorum.com | Nicole Raleigh
Multiple myeloma (MM) is an incurable haematological malignancy, but patient survival outcomes have been lately improved by recent advances in treatment. Despite this innovation, however, MM patients are at high risk of relapse and need prompt treatment to reduce the morbidity and mortality associated with the disease and its complications.
-
6 days ago | 
pharmaphorum.com | Nicole Raleigh
Tumour Treating Fields (TTFields) present a completely different approach to cancer therapy, involving alternating electric fields that, when applied to specific frequencies, can disrupt cancer cell division.
-
6 days ago | 
pharmaphorum.com | Nicole Raleigh
Optimising clinical trial screening requires clinical expertise and, now, artificial intelligence, reducing patient screening time and boosting trial enrolment, as well as addressing the risk of overtreatment. At ASCO 2025, web editor Nicole Raleigh spoke with Aaron Brauser, co-founder and CEO of Realyze Intelligence Healthcare Solutions, a Carta Healthcare company, about accelerating clinical trial and delivering real-world data (RWD).
-
1 week ago | 
pharmaphorum.com | Nicole Raleigh
As ASCO 2025 commenced in Chicago on Friday 30th May, pharmaphorum headed over to the Windy City’s Willis Tower for Johnson & Johnson’s exclusive Breathtaking event on the 99th floor. The cityscape surrounding the event far below, J&J launched its Breathtaking consumer activation for Rybrevant + Lazcluze, shining a spotlight on how this combination treatment gives patients more time to enjoy and cherish life’s most ‘breathtaking’ moments.
-
1 week ago | 
pharmaphorum.com | Nicole Raleigh
Trends can be predicted, and trends can unfold. Here, Liz Beatty – co-founder and chief strategy officer of Inato – speaks to the beginnings of a new era in drug development brought on by key technological advances in AI. Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as inaccessibility, lack of representation, and intense competition for participants.
-
1 week ago | 
pharmaphorum.com | Nicole Raleigh
As ASCO 2025 kicks off in Chicago, pharmaphorum looks back to a conversation with Pierre Fabre Laboratories at the ESMO congress last autumn, where we spoke with experts Théodore Leondaridis, Global Franchise Head, Innovative Oncology (Spain); Dr Francesco Hofmann, VP and Head of Research and Development (Switzerland); and Nuria Perez Cullell, Medical Director, Patient & Consumer.
